<DOC>
	<DOC>NCT00099333</DOC>
	<brief_summary>This study will look at the safety of substituting exenatide for insulin in patients with type 2 diabetes who are currently taking insulin and oral antidiabetic agent(s).</brief_summary>
	<brief_title>Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents</brief_title>
	<detailed_description>This is an exploratory, multicenter, open-label, 2-arm, parallel trial. Approximately 30 patients with type 2 diabetes, currently on a sulfonylurea, or meglitinide and/or metformin and insulin therapy, will be randomized to discontinue insulin and substitute it with exenatide or remain on their current diabetes therapy regimen. All patients will continue their current diet and exercise regimen during the study.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Patients have been treated with insulin for &gt;=3 months up to 12 years. HbA1c &lt;=10.5%. Body mass index (BMI) between 27 kg/m2 and 40 kg/m2. Patients previously received exenatide or GLP1 analogs. Patients have been treated for greater than 2 weeks with thiazolidinediones or alphaglucosidase inhibitors within 3 months prior to screening.</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>exenatide</keyword>
	<keyword>exendin-4</keyword>
	<keyword>Amylin</keyword>
	<keyword>Eli Lilly</keyword>
	<keyword>diabetes</keyword>
</DOC>